On the basis of the results of recent studies demonstrating the benefit of osimertinib after definitive surgery with or without adjuvant chemotherapy7 or chemo-RT in place of durvalumab8 in patients with EGFR-mutant disease, testing for AGAs should be performed in stage I to III NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.